Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Paradigm Biopharmaceuticals ( (AU:PAR) ).
Paradigm Biopharmaceuticals has made significant strides in FY25, transitioning from regulatory preparation to active clinical execution of its global Phase 3 trial for knee osteoarthritis treatment. The company has strengthened its financial platform with a $16 million equity raise and a $27 million convertible note facility, supporting trial execution and pipeline expansion. With patient enrolment underway and strategic acquisitions like Pentacoxib™, Paradigm is poised for a pivotal year in FY26, aiming to achieve key recruitment milestones and interim analysis, which could enhance clinical and commercial value.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd is a late-stage drug development company focused on creating new therapies to address unmet medical needs, particularly in the treatment of osteoarthritis. The company is actively involved in clinical trials and strategic asset acquisitions to expand its osteoarthritis pipeline, aiming to transform the treatment landscape for this condition.
Average Trading Volume: 802,643
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$115M
Find detailed analytics on PAR stock on TipRanks’ Stock Analysis page.